From precision medicine to genetic screening, here’s how Illumina is being unbundled.
Illumina’s sequencing business is at risk.
As the cost of gene sequencing technology continues to drop, Illumina has become increasingly reliant on selling its products that generate data by extracting, preparing, and sequencing biological samples.
However, the genomics space is beginning to shift, prioritizing products that analyze data over those that create it. Startups providing genomic analysis software and tools are rapidly gaining momentum. Funding to the sector reached a record high of $8.6B in 2021.
Illumina is also adapting its strategy to keep up. For example, it acquired liquid biopsy startup GRAIL and genomic analysis software platform BlueBee in 2020.
Below, we take a look at how startups are unbundling Illumina, from molecular diagnostics to agrigenomics to reproductive health, and more.
Want the full expert post? Become a CB Insights customer.
If you’re already a customer, log in here.
